Ghent University Academic Bibliography

Show Sort by

Your filters: cql: parent exact "NEURO-ONCOLOGY"

Mark
- conference
- C3
Absence of correlation between necrosis volume and overall survival in glioblastoma

Giorgio Hallaert (UGent) , Harry Pinson, Caroline Vandenbroecke, Dimitri Vanhauwaert, Dirk Van Roost (UGent) and Tom Boterberg (UGent)

(2018) NEURO-ONCOLOGY. 20(suppl. 3). p.iii229-iii229
Mark
The role of PET- and MRI-derived [18F]FET PET parameters in the discrimination of low- and high-grade gliomas

Sam Donche (UGent) , Michaël Henrotte, Stijn Bonte (UGent) , Jeroen Verhoeven (UGent) , Caroline Van den Broecke (UGent) , Marjan Acou (UGent) and Ingeborg Goethals (UGent)

(2018) NEURO-ONCOLOGY. 20(suppl. 3). p.iii241-iii241
Mark
- conference
- C3
- open access
Cost-effectiveness of [18F]FET for therapy assessment of temozolomide for patients with glioblastoma in a Belgian healthcare setting

Tristan Baguet (UGent) , Jeroen Verhoeven (UGent) , Filip De Vos (UGent) and Ingeborg Goethals (UGent)

(2018) NEURO-ONCOLOGY. 20(suppl. 3).
Mark
- conference
- C3
Radiomics and machine learning on [18F]FET PET and T1ce MRI discriminate between low-grade and high-grade glioma

Stijn Bonte (UGent) , Sam Donche (UGent) , Michaël Henrotte, Roel Van Holen (UGent) and Ingeborg Goethals (UGent)

(2018) NEURO-ONCOLOGY. 20(suppl. 3). p.iii226-iii226
Mark
- conference
- C3
- open access
In vitro and in vivo evaluation of the LAT1 PET tracer 2-[18F]FELP in comparison to [18F]FET and [18F]FDG

Jeroen Verhoeven (UGent) , Julie Bolcaen (UGent) , Ken Kersemans (UGent) , Valerie De Meulenaere (UGent) , Benedicte Descamps (UGent) , Jean-Pierre Kalala Okito (UGent) , Caroline Van den Broecke (UGent) , Karel Deblaere (UGent) , Christian Vanhove (UGent) , Ingeborg Goethals (UGent) , et al.

(2017) NEURO-ONCOLOGY. 19(suppl. 3). p.46-46
Mark
- conference
- C3
Automated grade prediction of glioma patients based on magnetic resonance imaging and a random forests approach

Stijn Bonte (UGent) , Ingeborg Goethals (UGent) and Roel Van Holen (UGent)

(2016) Neuro-Oncology. 18(Supplement 4). p.iv38-iv38
Mark
- conference
- C3
Combination of gene copy gain and epigenetic deregulation are associated with the aberrant expression of a stem cell related HOX-signature in glioblastoma

Sebastian Kurscheid, Pierre Bady, Davide Sciuscio, Ivana Samarzija, Tal Shay, Irene Vassallo, Wim Van Criekinge (UGent) , Eytan Domany, Roger Stupp, Mauro Delorenzi, et al.

(2014) NEURO-ONCOLOGY. 16(suppl. 5).
Mark
- conference
- C3
Use of 18F-fluoromethylcholine PET in early treatment response assessment in glioblastoma patients

Julie Bolcaen (UGent) , Marjan Acou (UGent) , Tom Boterberg (UGent) , Karel Deblaere (UGent) , F De Vos, GIORGIO HALLAERT (UGent) , Jean-Pierre Kalala Okito (UGent) and C Van den Broecke

(2014) NEURO-ONCOLOGY. 16(suppl. 2).
Mark
Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas

Annette Künkele, Katleen De Preter (UGent) , Lukas Heukamp, Theresa Thor, Kristian W Pajtler, Wolfgang Hartmann, Michel Mittelbronn, Michael A Grotzer, Hedwig E Deubzer, Franki Speleman (UGent) , et al.

(2012) NEURO-ONCOLOGY. 14(7). p.859-869
Mark
- conference
- C3
Safety analysis of randomized Belgian phase II trial of extended use of adjuvant temozolomide in newly diagnosed glioblastoma patients

L Renard, PM Clement, F Hammouch, Tom Boterberg (UGent) , V Verschaeve, N Whenham, C Mitine, D Devriendt and J Baurain

(2010) NEURO-ONCOLOGY. 12(Suppl. 3). p.46-47

Academic Bibliography

Absence of correlation between necrosis volume and overall survival in glioblastoma

The role of PET- and MRI-derived [18F]FET PET parameters in the discrimination of low- and high-grade gliomas

Cost-effectiveness of [18F]FET for therapy assessment of temozolomide for patients with glioblastoma in a Belgian healthcare setting

Radiomics and machine learning on [18F]FET PET and T1ce MRI discriminate between low-grade and high-grade glioma

In vitro and in vivo evaluation of the LAT1 PET tracer 2-[18F]FELP in comparison to [18F]FET and [18F]FDG

Automated grade prediction of glioma patients based on magnetic resonance imaging and a random forests approach

Combination of gene copy gain and epigenetic deregulation are associated with the aberrant expression of a stem cell related HOX-signature in glioblastoma

Use of 18F-fluoromethylcholine PET in early treatment response assessment in glioblastoma patients

Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas

Safety analysis of randomized Belgian phase II trial of extended use of adjuvant temozolomide in newly diagnosed glioblastoma patients

Contents

Support

Contact